Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

39.40 -0.63 (-1.57%)
Streaming Delayed Price Updated: 2:21 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
The Ultimate Biotech Stock to Buy With $50 Right Now
This innovative drugmaker still has plenty of upside potential. 
Via The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening
Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock
Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector. 
Via Chartmill
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Both should have significant catalysts by the end of the decade. 
Via The Motley Fool
17 Analysts Have This To Say About Exelixis
 
Via Benzinga
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
Is the Market Bullish or Bearish on Exelixis?
 
Via Benzinga
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Undervalued Stock with Strong Fundamentals
EXELIXIS (EXEL) emerges as a top value stock with strong fundamentals: undervalued, zero debt, high profitability, and solid growth in the biotech sector. 
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Embodies the Affordable Growth Investment Strategy
Exelixis (EXEL) offers affordable growth with strong oncology revenue, high profitability, a robust balance sheet, and attractive valuation metrics. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity
Exelixis (EXEL) is a strong value investing candidate, trading below intrinsic value with a solid financial profile, high profitability, and strong growth prospects. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Growth at a Reasonable Price (GARP) Stock
EXELIXIS INC (EXEL) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity. 
Via Chartmill
Exelixis Inc (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Setup
Exelixis (EXEL) is a strong growth stock with solid fundamentals—17.5% revenue growth, high profitability, and no debt—plus a bullish technical setup, signaling a potential breakout opportunity. 
Via Chartmill
The Analyst Verdict: Exelixis In The Eyes Of 19 Experts
 
Via Benzinga
Exelixis EXEL Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts. 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL): A Strong Value Investment with Undervalued Potential and Solid Fundamentals
EXELIXIS (EXEL) is a top value stock with strong fundamentals—undervalued P/E, zero debt, high profitability, and solid growth. Ideal for value investors seeking quality at a discount. 
Via Chartmill
Assessing Exelixis: Insights From 20 Financial Analysts
 
Via Benzinga
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events. 
Via Benzinga
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans
Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update. 
Via Benzinga
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Exelixis Q2 Revenue Falls 11 Percent
Via The Motley Fool
Topics Earnings Intellectual Property
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL): A Prime Example of Affordable Growth in Biotech
EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk. 
Via Chartmill
Topics Bankruptcy
Uncovering Potential: Exelixis's Earnings Preview
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Breakout Potential
EXELIXIS INC (EXEL) combines strong growth fundamentals—high profitability, solid financials, and rising revenue—with bullish technical signals, making it a promising breakout candidate for investors. 
Via Chartmill
Earnings Scheduled For July 28, 2025
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors and breakout traders. 
Via Chartmill
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.